The Personalized Medicines In Oncology Market deals with the development of medicines to provide effective cancer treatment. Personalized medicine is a drug which has the ability to offer the right drug to the right patient at the right time for the right disease with the right dosage.
Personalized medicine application has the largest network, mainly due to high demand for better cancer treatment. Also, it has vast expansion opportunities in its application such as biomarkers, discovery, cancer and research application. This market provides the services like molecular oncopathology, genome diagnostics, radiation treatment, oncology testing, cancer chemotherapy and some others also. These medicines are gaining popularity due to their effectiveness in cancer patients and patients suffering with rare genetic disorders.
Scope & Regional Forecast of the Personalized Medicines In Oncology Market
Different types of tools and services are provided and speeding up the development in the cancer therapeutics field and help in boosting the growth of the Personalized Medicines In Oncology Market. This market is expected to witness significant growth due to increasing disease incidence and deep focus of creating medicines for cancer patients where effectiveness has been proved to be higher as compared to other therapies. However, complex nature of drugs, higher costs for R & D are the key restraints for the market growth.
Americas and Europe are dominating the Personalized Medicines In Oncology Market in terms of revenue, due to increasing number of cancer patients. Asia-Pacific is expected to register rapid growth during the forecast period, due to accelerating development of R & D infrastructure. The ongoing research and legal initiatives I personalized medicine in Japan will promote the growth opportunities for the market.
Segmentations & Key Players Involved in the Personalized Medicines In Oncology Market
According to IndustryARC findings, the Personalized Medicines In Oncology Market can be broken down into various segmentations on the basis of –
Tumor Type: Genomics, Proteomics, Metabolomics and Epigenetics.
Service: Molecular Oncopathology, Genome Diagnostics, Radiation Therapy, Oncology Testing, Chemotherapy and Others.
Occurrence: Colorectal/ stomach/ esophageal, Ovarian, Lung, Brest, Sarcoma, Pancreatic, Cancer, Mesothelioma and Others.
Technology: Next-Generation Sequencing, Fluorescence/ Chromogenic In Situ Hybridization, Immunohistochemistry, Microarray, Quantitative PCR, High Throughput SNP Analysis and Others.
End User: Research Centers, Governmental Institutions, Hospitals and Others.
Region: Americas, Europe, Asia-Pacific and Rest of the World.
Some of the key players involved according to IndustryArc:
Agendia Nv
Ariana Pharma
Caris Life Sciences
Foundation Medicine
Life Technologies Corporation
Request For Toc @ http://www.industryarc.com/pdfdownload.php?id=15245